Promomed has set the IPO price at ₽400 per share, which corresponds to the upper end of the price range. Volume of placement amounted to about ₽6 billion, and the entire company is valued at ₽85 billion. Promomed will use the raised funds to develop, register and bring to market new innovative drugs, as well as consider options for partial deleveraging and capital structure optimization. Trading in the company's shares starts today under the ticker PRMD.